

Chronic Neurologic Disorders

Daniel A. Handel

Sarah Andrus Gaines

REFERENCES

- Kiernan MC, Vucic S, Cheah BC, et al: Amyotrophic lateral sclerosis. *Lancet* 377: 942, 2011. [PMID: 21296405]
- Naganska E, Matyja E: Amyotrophic lateral sclerosis—looking for pathogenesis and effective therapy. *Folia Neuropathol* 49: 1, 2011. [PMID: 21455838]
- Gordon PH: Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management. *CNS Drugs* 25: 1, 2011. [PMID: 21128691]
- Hardiman O, van den Berg LH, Kiernan MC: Clinical diagnosis and management of amyotrophic lateral sclerosis. *Nat Rev Neurol* 7: 639, 2011. [PMID: 21989247]
- Swash M: Early diagnosis of ALS/MND. *J Neurol Sci* 160 (Suppl 1): S33, 1998. [PMID: 9851646]
- Sostarko M, Vranjes D, Brinar V, Brzovic Z: Severe progression of ALS/MND after intervertebral discectomy. *J Neurol Sci* 160 (Suppl 1): S42, 1998. [PMID: 9851648]
- Wilbourn AJ: Clinical neurophysiology in the diagnosis of amyotrophic lateral sclerosis: the Lambert and the El Escorial criteria. *J Neurol Sci* 160 (Suppl 1): S25, 1998. [PMID: 9851644]
- Kaufmann P, Levy G, Montes J, et al: Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. *Amyotroph Lateral Scler* 8: 42, 2007. [PMID: 17364435]
- Agosta F, Chiò A, Cosottini M, et al: The present and the future of neuroimaging in amyotrophic lateral sclerosis. *Am J Neuroradiol* 31: 1769, 2010. [PMID: 20360339]
- Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 49: 657, 1997. [PMID: 9305318]
- Miller RG, Mitchell JD, Lyon M, Moore DH: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Cochrane Database Syst Rev* 1: CD001447, 2007. [PMID: 17253460]
- Miller RG, Jackson CE, Kasarskis EJ, et al: Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional and respiratory therapies (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. *Neurology* 73: 1218, 2009. [PMID: 19822872]
- Andersen PM, Borasio GD, Dengler R, et al: EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. *Eur J Neurol* 12: 921, 2005. [PMID: 16324086]
- Chen A, Montes J, Mitsumoto H: The role of exercise in amyotrophic lateral sclerosis. *Phys Med Rehabil Clin North Am* 19: 545, 2008. [PMID: 18625415]
- Angelini C: Diagnosis and management of autoimmune myasthenia gravis. *Clin Drug Invest* 31: 1, 2011. [PMID: 21053987]
- Gilbert ME, Savino PJ: Ocular myasthenia gravis. *Int Ophthalmol Clin* 47: 93, 2007. [PMID: 18049283]
- Kleiner-Fisman G, Kott HS: Myasthenia gravis mimicking stroke in elderly patients. *Mayo Clin Proc* 73: 1077, 1998. [PMID: 9818042]
- Montero-Odasso M: Dysphonia as first symptom of late-onset myasthenia gravis. *J Gen Intern Med* 21: C4, 2006. [PMID: 16808732]
- García-Carrasco M, Escarcega RO, Fuentes-Alexandro S, et al: Therapeutic options in autoimmune myasthenia gravis. *Autoimmun Rev* 6: 373, 2007. [PMID: 17537383]
- Kumar V, Kaminski HJ: Treatment of myasthenia gravis. *Curr Neurol Neurosci Rep* 11: 89, 2011. [PMID: 20927659]
- Maggi L, Mantegazza R: Treatment of myasthenia gravis: focus on pyridostigmine. *Clin Drug Invest* 31: 691, 2011. [PMID: 21815707]
- Gronseth GS, Barohn RJ: Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 55: 7, 2000. [PMID: 10891896]
- Dural K, Yildirim E, Han S, et al: The importance of the time interval between diagnosis and operation in myasthenia gravis patients. *J Cardiovasc Surg (Torino)* 44: 125, 2003. [PMID: 12627084]
- Richman DP, Agius MA: Treatment of autoimmune myasthenia gravis. *Neurology* 61: 1652, 2003. [PMID: 14694025]
- Palace J, Newsom-Davis J, Lecky B: A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. *Neurology* 50: 1778, 1998. [PMID: 9633727]
- Zinman L, Ng E, Bril V: IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. *Neurology* 68: 837, 2007. [PMID: 17353471]
- Gajdos P, Chevret S, Toyka K: Intravenous immunoglobulin for myasthenia gravis. *Cochrane Database Syst Rev* 1: CD002277, 2008. [PMID: 18254004]
- Baraka A: Anesthesia and critical care of thymectomy for myasthenia gravis. *Chest Surg Clin North Am* 11: 337, 2001. [PMID: 11413760]
- Barrons RW: Drug-induced neuromuscular blockade and myasthenia gravis. *Pharmacotherapy* 17: 1220, 1997. [PMID: 9399604]
- Jani-Acsadi A, Lisak RP: Myasthenic crisis: guidelines for prevention and treatment. *J Neurol Sci* 261: 127, 2007. [PMID: 17544450]
- Benatar M, Kaminski HJ: Quality Standards Subcommittee of the American Academy of Neurology: evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 68: 2144, 2007. [PMID: 17460154]
- Skeie GO, Apostolski S, Evoli A, et al: Guidelines for treatment of autoimmune neuromuscular transmission disorders. *Eur J Neurol* 17: 893, 2010. [PMID: 20402760]
- Hart IK, Sharshar T, Sathasivam S: Immunosuppressant drugs for myasthenia gravis. *J Neurol Neurosurg Psychiatry* 80: 5, 2009. [PMID: 19091704]
- Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR: Corticosteroids for myasthenia gravis. *Cochrane Database Syst Rev* 2: CD002828, 2005. [PMID: 15846640]
- Ragonese P, Aridon P, Salemi G, D'Amelio M, Savettieri G: Mortality in multiple sclerosis: a review. *Eur J Neurol* 15: 123, 2008. [PMID: 18217882]
- Sobel RA: The pathology of multiple sclerosis. *Neurol Clin* 13: 1, 1995. [PMID: 7739499]
- Farez MF, Correale J: Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. *J Neurol* 258: 1197, 2011. [PMID: 21431896]
- Koch M, Uyttenboogaart M, Polman S, De Keyser J: Seizures in multiple sclerosis. *Epilepsia* 49: 948, 2008. [PMID: 18336559]
- Poser CM, Brinar VV: Diagnostic criteria for multiple sclerosis. *Clin Neurol Neurosurg* 103: 1, 2001. [PMID: 11311469]
- Kragt JJ, Thompson AJ, Montalban X, et al: Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. *Neurology* 70: 1084, 2008. [PMID: 18184917]
- Swanton JK, Rovira A, Tintore M, et al: MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. *Lancet Neurol* 6: 677, 2007. [PMID: 17616439]
- Goodin DS, Frohman EM, Garmany GP, et al: Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. *Neurology* 58: 169, 2002. [PMID: 11805241]
- Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. *Clin Ther* 28: 461, 2006. [PMID: 16750460]
- Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J: Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. *Neurology* 51: 529, 1998. [PMID: 9710030]
- Thrower BW: Relapse management in multiple sclerosis. *Neurologist* 15: 1, 2009. [PMID: 19131851]
- Heesen C, Solari A, Giordano A, Kasper J, Köpke S: Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement. *J Neurol Sci* 306: 192, 2011. [PMID: 20920815]
- Dudsek A, Zettl UK: Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis. *J Neurol* 253 (Suppl 5): V50, 2006. [PMID: 16998754]
- Goodin DS, Cohen BA, O'Connor P, et al: Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 71: 766, 2008. [PMID: 18765653]
- Goodin DS, Arnason BG, Coyle PK, et al: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 61: 1332, 2003. [PMID: 14638950]
- Frohman EM, Goodin DS, Calabresi PA, et al: The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 61: 602, 2003. [PMID: 12963748]
- Burks JS, Noronha A: Guidelines on use of anti-IFN- β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN- β antibodies in multiple sclerosis. *Eur J Neurol* 14: e8, 2007. [PMID: 17539931]
- Elovaara I, Apostolski S, van Doorn P, et al: EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. *Eur J Neurol* 15: 893, 2008. [PMID: 18796075]
- Filippi M, Rocca MA, Arnold DL, et al: EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. *Eur J Neurol* 13: 313, 2006. [PMID: 16643308]
- Sellebjerg F, Barnes D, Filippini G, et al: EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. *Eur J Neurol* 12: 939, 2005. [PMID: 16324087]
- Pucci E, Branäs P, D'Amico R, et al: Amantadine for fatigue in multiple sclerosis. *Cochrane Database Syst Rev* 1: CD002818, 2007. [PMID: 17253480]
- Casetta I, Iuliano G, Filippini G: Azathioprine for multiple sclerosis. *Cochrane Database Syst Rev* 4: CD003982, 2007. [PMID: 17943809]
- Vedula SS, Brodney-Folse S, Gal RL, Beck R: Corticosteroids for treating optic neuritis. *Cochrane Database Syst Rev* 1: CD001430, 2007. [PMID: 17253459]
- La Mantia L, Milanese C, Mascoli N, et al: Cyclophosphamide for multiple sclerosis. *Cochrane Database Syst Rev* 1: CD002819, 2007. [PMID: 17253481]
- Martinelli Boneschi F, Rovaris M, Capra R, Comi G: Mitoxantrone for multiple sclerosis. *Cochrane Database Syst Rev* 4: CD002127, 2005. [PMID: 16235298]
- Farinotti M, Simi S, Di Pietrantonj C, et al: Dietary interventions for multiple sclerosis. *Cochrane Database Syst Rev* 1: CD004192, 2007. [PMID: 17253500]
- Mills RJ, Yap L, Young CA: Treatment for ataxia in multiple sclerosis. *Cochrane Database Syst Rev* 1: CD005029, 2007. [PMID: 17253537]
- Takamori M: Lambert-Eaton myasthenic syndrome as an autoimmune calcium channelopathy. *Biochem Biophys Res Commun* 322: 1347, 2004. [PMID: 15336982]
- Flink MT, Atchison WD: Ca²⁺ channels as targets of neurological disease: Lambert-Eaton syndrome and other Ca²⁺ channelopathies. *J Bioenerg Biomembr* 35: 697, 2003. [PMID: 15000529]

64. Nakao YK, Motomura M, Fukudome T, et al: Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. *Neurology* 59: 1773, 2002. [PMID: 12473768]
65. Wirtz PW, Wintzen AR, Verschuuren JJ: Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. *Muscle Nerve* 32: 226, 2005. [PMID: 15793845]
66. Newsom-Davis J: Lambert-Eaton myasthenic syndrome. *Rev Neurol (Paris)* 160: 177, 2004. [PMID: 15034474]
67. Quartel A, Turbeville S, Lounsbury D: Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. *Curr Med Res Opin* 26: 1363, 2010. [PMID: 20377318]
68. Titulaer MJ, Lang B, Verschuuren JJGM: Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. *Lancet Neurol* 10: 1098, 2011. [PMID: 22094130]
69. Pascuzzi RM: Myasthenia gravis and Lambert-Eaton syndrome. *Ther Apher* 6: 57, 2002. [PMID: 11886578]
70. Verschuuren JJ, Wirtz PW, Titulaer MJ, et al: Available treatment options for the management of Lambert-Eaton myasthenic syndrome. *Expert Opin Pharmacother* 7: 1323, 2006. [PMID: 16805718]
71. Vedeler CA, Antoine JC, Giometto B, et al: Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. *Eur J Neurol* 13: 682, 2006. [PMID: 16834698]
72. Keogh M, Sedehizadeh S, Maddison P: Treatment for Lambert-Eaton myasthenic syndrome. *Cochrane Database Syst Rev* 2: CD003279, 2011. [PMID: 21328260]
73. Feasby T, Banwell B, Benstead T, et al: Guidelines on the use of intravenous immune globulin for neurologic conditions. *Transfus Med Rev* 21 (Suppl 1): S57, 2007. [PMID: 17397768]
74. Gershanik OS: Clinical problems in late-stage Parkinson's disease. *J Neurol* 257 (Suppl 2): S288, 2010. [PMID: 21080191]
75. Stamey W, Jankovic J: Impulse control disorders and pathological gambling in patients with Parkinson disease. *Neurologist* 14: 89, 2008. [PMID: 18332838]
76. Factor SA: Current status of symptomatic medical therapy in Parkinson's disease. *Neurotherapeutics* 5: 164, 2008. [PMID: 18394561]
77. Eberling JL, Jagust WJ, Christine CW, et al: Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. *Neurology* 70: 1980, 2008. [PMID: 18401019]
78. Fox SH, Katzenschlager R, Lim S-Y, et al: The Movement Disorder Society evidence-based medicine review update: treatments for motor symptoms of Parkinson's disease. *Mov Disord* 26: S2, 2011. [PMID: 22021173]
79. Hickey P, Stacy M: Available and emerging treatments for Parkinson's disease: a review. *Drug Des Devel Ther* 5: 241, 2011. [PMID: 21607020]
80. Hallett M, Litvan I: Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The Task Force on Surgery for Parkinson's Disease. *Neurology* 53: 1910, 1999. [PMID: 10599758]
81. Uitti RJ, Wharen RE, Turk MF: Efficacy of levodopa therapy on motor function after posteroventral pallidotomy for Parkinson's disease. *Neurology* 51: 1755, 1998. [PMID: 9855542]
82. Chumakov K, Ehrenfeld E: New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. *Clin Infect Dis* 47: 1587, 2008. [PMID: 18990066]
83. Bartels MN, Omura A: Aging in polio. *Phys Med Rehabil Clin North Am* 16: 197, 2005. [PMID: 15561551]
84. Boyer FC, Tiffreau V, Rapin A, et al: Post-polio syndrome: pathophysiological hypothesis, diagnosis criteria, medication therapeutics. *Ann Phys Rehabil Med* 53: 34, 2010. [PMID: 20093102]
85. Wekre LL, Stanghelle JK, Lobben B, Oyhaugen S: The Norwegian Polio Study 1994: a nationwide survey of problems in long-standing poliomyelitis. *Spinal Cord* 36: 280, 1998. [PMID: 9589529]
86. Bruno RL: Abnormal movements in sleep as a post-polio sequelae. *Am J Phys Med Rehabil* 77: 339, 1998. [PMID: 9715925]
87. Gonzalez H, Olsson T, Borg K: Management of postpolio syndrome. *Lancet Neurol* 9: 634, 2010. [PMID: 20494327]
88. Tiffreau V, Rapin A, Serafi R, et al: Post-polio syndrome and rehabilitation. *Ann Phys Rehabil Med* 53: 42, 2010. [PMID: 20044320]
89. On AY, Oncu J, Uludag B: Effects of lamotrigine on the symptoms and life qualities of patients with post polio syndrome: a randomized, controlled study. *NeuroRehabilitation* 20: 245, 2005. [PMID: 16403993]

■ USEFUL WEB RESOURCES

- ALS Association: Provides information and support options for amyotrophic lateral sclerosis patients and clinicians—<http://www.alsa.org>
- Myasthenia Gravis Foundation of America, Inc.: Symptomatic and therapeutic information for myasthenia gravis patients and clinicians—<http://www.myasthenia.org>
- National Institute of Neurological Disorders and Stroke: Fact sheet on myasthenia gravis, as well as contact information for support organizations—http://www.ninds.nih.gov/disorders/myasthenia_gravis/detail_myasthenia_gravis.htm
- National Institute of Neurological Disorders and Stroke: NINDS Amyotrophic Lateral Sclerosis Information Page—<http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/ALS.htm>
- National Institute of Neurological Disorders and Stroke: NINDS Multiple Sclerosis Information Page with information on the diagnosis and treatment of multiple sclerosis, along with organization and contact information—http://www.ninds.nih.gov/disorders/multiple_sclerosis/multiple_sclerosis.htm
- National Multiple Sclerosis Society: Community support, fundraising, research prospects, information on multiple sclerosis—<http://www.nationalmssociety.org/index.aspx>
- National Parkinson Foundation: Information for patients and physicians and research prospects—<http://www.parkinson.org>
- Post-Polio Health International: General information on living independently with polio, as well as research on amelioration of disease symptoms—<http://www.post-polio.org/>